Abstract-5-Hydroxy-2-aminovaleric acid (HAVA) has been suggested to be a specific marker of oxidation of apolipoprotein (apo) B-100 proline (Pro) and arginine (Arg) side-chain residues in low density lipoprotein (LDL) in vitro. Here we describe the application of sensitive mass spectrometric techniques to the characterization of Pro/Arg-modified apoB-100 in LDL 1 (S f 7 to 12) and LDL 2 (S f 0 to 7) in vivo. We studied 7 subjects with familial defective apoB-100 (FDB) and 8 normolipidemic controls. In FDB subjects, the presence of a mutant apoB-100 (FDB 3500Q ) in LDL markedly reduced its affinity for the LDL receptor, leading to increased residence times (RTs) of LDL 1 (65Ϯ21 versus 32Ϯ12 hours, PϽ0.005) and LDL 2 (230Ϯ40 versus 53Ϯ7 hours, PϽ0.001) when compared with controls, as determined by stable-isotope turnover studies. LDL 1 HAVA content was not different between the groups (FDB, 0.004Ϯ0.001 mol/mol apoB-100 versus controls, 0.003Ϯ0.001 mol/mol apoB-100, Pϭ0.200). LDL 2 HAVA content was higher in FDB subjects (0.374Ϯ0.088 versus 0.013Ϯ0.002 mol/mol apoB-100, PϽ0.001). In both groups, LDL 2 HAVA was positively associated with LDL 2 RT (FDB, rϭ0.893, Pϭ0.003; controls, rϭ0.976, Pϭ0.000) and negatively correlated with LDL 2 ␣-tocopherol content (FDB, rϭϪ0.929, Pϭ0.003; controls, rϭϪ0.903, Pϭ0.002). No significant correlations could be found between LDL 1 HAVA, LDL 1 RT, and ␣-tocopherol, respectively. The low LDL 1 HAVA content observed in both FDB and control groups was thought to be due to the relatively lower RT as well as the higher ␣-tocopherol content of these lipoproteins. In contrast, LDL 2 seemed to be strongly prone to direct oxidation of apoB-100 in vivo. The longer these particles linger in the circulation, the more apoB-100 Pro/Arg residues become modified. Key Words: familial defective apolipoprotein B-100 Ⅲ lipoproteins Ⅲ residence time Ⅲ oxidation Ⅲ atherosclerosis O xidative modification of LDL lipids and apoB-100 by reactive oxygen species (ROS) is widely regarded as a crucial event in atherogenesis. 1,2 ApoB-100 modifications, eg, binding of lipid peroxidation products or direct oxidation of amino acid side-chain residues, are thought to finally result in the formation of new epitopes that are specifically recognized by scavenger receptors. 1,2 However, despite convincing evidence from in vitro and animal experiments, data concerning the role of oxidized apoB-100 in the development of atherosclerosis in humans in vivo are scarce. One reason for this is the shortage of sensitive and specific methods for direct measurement of oxidized apoB-100 in circulating LDL. Recent studies have described the determination of circulating autoantibodies to oxidized LDL, the measurement of specific stable oxidation products of LDL apoB-100 isolated from human atherosclerotic tissue (eg, 3-chlorotyrosine or nitrotyrosine), or the measurement of stable oxidation products of tyrosine, valine, lysine, and phenylalanine side-chain residues of total LDL protein obtained from human plasma. [3] [4] [5] More recently, the oxidation of LDL apoB-100 proline (Pro) and arginine (Arg) residues primarily to ␥-glutamyl semialdehyde, which by reduction forms 5-hydroxy-2-aminovaleric acid (HAVA), has been measured in vitro and in normolipidemic subjects in vivo. 6 However, the value of HAVA as a specific marker of LDL apoB-100 oxidation under pathophysiological conditions such as hypercholesterolemia has not been established. Oxidative damage of LDL apoB-100 is believed to substantially occur in the subendothelial space of the vessel wall. 1 During circulation, LDL particles enter and reemerge from the subendothelium. 2, 7 Under hypercholesterolemic conditions, eg, in subjects with familial defective apoB-100 (FDB), the time needed to remove LDL from the circulation is drastically increased. 8 This should favor an increase in the number of LDL particles that are exposed to the subendothelium and in the duration of LDL apoB-100 exposure to ROS. Furthermore, compositional changes in LDL particles possibly result in different exposures of both lipids and apoB-100 to ROS. 1,7,9 Thus, 
O xidative modification of LDL lipids and apoB-100 by reactive oxygen species (ROS) is widely regarded as a crucial event in atherogenesis. 1, 2 ApoB-100 modifications, eg, binding of lipid peroxidation products or direct oxidation of amino acid side-chain residues, are thought to finally result in the formation of new epitopes that are specifically recognized by scavenger receptors. 1, 2 However, despite convincing evidence from in vitro and animal experiments, data concerning the role of oxidized apoB-100 in the development of atherosclerosis in humans in vivo are scarce. One reason for this is the shortage of sensitive and specific methods for direct measurement of oxidized apoB-100 in circulating LDL. Recent studies have described the determination of circulating autoantibodies to oxidized LDL, the measurement of specific stable oxidation products of LDL apoB-100 isolated from human atherosclerotic tissue (eg, 3-chlorotyrosine or nitrotyrosine), or the measurement of stable oxidation products of tyrosine, valine, lysine, and phenylalanine side-chain residues of total LDL protein obtained from human plasma. [3] [4] [5] More recently, the oxidation of LDL apoB-100 proline (Pro) and arginine (Arg) residues primarily to ␥-glutamyl semialdehyde, which by reduction forms 5-hydroxy-2-aminovaleric acid (HAVA), has been measured in vitro and in normolipidemic subjects in vivo. 6 However, the value of HAVA as a specific marker of LDL apoB-100 oxidation under pathophysiological conditions such as hypercholesterolemia has not been established. Oxidative damage of LDL apoB-100 is believed to substantially occur in the subendothelial space of the vessel wall. 1 During circulation, LDL particles enter and reemerge from the subendothelium. 2, 7 Under hypercholesterolemic conditions, eg, in subjects with familial defective apoB-100 (FDB), the time needed to remove LDL from the circulation is drastically increased. 8 This should favor an increase in the number of LDL particles that are exposed to the subendothelium and in the duration of LDL apoB-100 exposure to ROS. Furthermore, compositional changes in LDL particles possibly result in different exposures of both lipids and apoB-100 to ROS. 1, 7, 9 Thus, individuals with hypercholesterolemia not only possess more circulating LDL but also have older, modified LDL. In this context, we hypothesized that the longer LDL particles linger in the circulation, the more Pro and Arg residues of apoB-100 should be modified. To prove this hypothesis, the present study combined specific and sensitive gas chromatographymass spectrometry (GC-MS) methodologies to measure both HAVA formation and retention times of native LDL in vivo in FDB subjects and normolipidemic controls.
Methods

Subjects
Seven subjects with heterozygous FDB (3 men and 4 women; 21 to 63 years old) and 8 normolipidemic control subjects (4 men and 4 women; 20 to 51 years old) volunteered for the study. All subjects were nonsmokers and were free of renal, hepatic, hematological, and thyroid abnormalities, and all medications known to affect lipid levels were discontinued at least 6 weeks before the study. No subject was taking antioxidants such as probucol and vitamins A or E. All subjects were normoglycemic. All subjects gave informed, written consent; ethical approval was granted by the local ethics committee. Fasting blood samples were collected into tubes containing EDTA at a final concentration of 0.1%. The blood was centrifuged at 4°C (2000g for 10 minutes) to separate cells from plasma. Blood plasma and LDL samples were all processed in subdued light to prevent any photooxidation of LDL. All buffers and solutions were degassed and stored under argon. Buoyant LDL 1 (S f 7 to 12) and small, dense LDL 2 (S f 0 to 7) were isolated from plasma by a combination of both cumulative and sequential gradient ultracentrifugation techniques as previously described. 8 Total LDL protein was determined by the bicinchoninic acid protein assay (Pierce) with bovine serum albumin as the protein standard. LDL apoB-100 was measured by immunoelectrophoresis (Sebia). LDL cholesterol was determined enzymatically by using CHOD-PAP test kits (Roche). The total carbonyl group content in LDL apoB-100 and LDL ␣-tocopherol content were measured as described elsewhere and are expressed as mol/mol of apoB-100. 6, 9, 10 Determination of HAVA Delipidation of LDL, formation of HAVA by reduction of ␥-glutamyl semialdehyde with NaBH 4 , and enzymatic hydrolysis of apoB-100 with nonspecific bacterial protease type XIV (Sigma Chemical Co) were performed as previously described. 6 The free amino acids were isolated from protein hydrolysates, derivatized to their N(O)-ethoxycarbonyl ethyl ester derivatives, and analyzed by electron-impact ionization GC-MS by following the protocol described elsewhere. 6,11 LDL HAVA content is expressed as mol/mol of apoB-100. The intra-assay coefficient of variation was Ͻ4.5%,and the interassay coefficient of variation, Ͻ6.1%.
Determination of LDL ApoB-100 Residence Time
The determination of LDL apoB-100 residence time (RT) in FDB and control subjects has been described elsewhere. 8 In brief, the stable-isotope tracers used were L-[ring- 13 
) was continued for 12 hours. Blood samples were obtained before the priming bolus; at 10-minute intervals for 2 hours; and after 2, 2.5, 3, 3.5, 4, 5, 6, 9, 10, 11, 12, 24, 48, and 72 hours. ApoB-100 of LDL subfractions was separated by preparative polyacrylamide gel electrophoresis. The stained apoB-100 bands were excised from gels and hydrolyzed. The free amino acids were isolated from apoB-100 hydrolysates by cation-exchange chromatography and then derivatized, and isotopic enrichment was determined by GC-MS. The kinetic parameters of LDL apoB-100 metabolism were estimated by multicompartmental analysis using the SAAM (simulation analysis and modeling, version 31) software package as previously published. 8 After fitting the model to the tracer data, LDL All lipid and protein values were determined at the time of the study, when all medications known to affect lipid levels were discontinued at least 6 weeks before the study. Clinical, biochemical, and kinetic parameters of FDB patients 1, 2, 3, 5, and 6 and control subjects 1, 2, 3, 4, 7, and 8 have been published in detail elsewhere. 8 *PϽ0.01 (Mann-Whitney test) for the difference between patients and normolipidemic controls.
apoB-100 fractional catabolic rates and RTs were determined with reasonable certainty on the basis of the fractional standard deviations of the model parameter estimates. 8 In our studies, LDLs were fractionated into 2 subclasses of particles: "buoyant" LDL 1 and smaller, more dense LDL 2 . Here, the enrichment curves clearly indicated that the labeling of LDL 1 preceded that of LDL 2 ; hence, they were modeled as precursor and product, respectively. 8
Statistical Analysis
Descriptive data were expressed as arithmetic meansϮSDs. Statistical analyses (Mann-Whitney tests, Spearman rank correlation analysis) were calculated by using the SPSS 9.0 software package.
Results
FDB patients had significantly higher levels of plasma total cholesterol, plasma apoB-100, and cholesterol and apoB-100 levels of LDL 1 and LDL 2 (Tables I and II) , whereas the concentrations of plasma triglycerides and lipoprotein constituents of VLDL, IDL, and HDL particles were not different between the 2 groups (statistical results not shown in detail). 8 The mean lipoprotein mass composition of LDL 1 and LDL 2 particles, ie, the mass percentage of cholesterol and apoB-100 of total lipoprotein mass, did not differ between the 2 groups. Furthermore, the ␣-tocopherol content in LDL 1 and LDL 2 particles was similar in the 2 groups. However, in both groups, the ␣-tocopherol content in LDL 1 was significantly higher when compared with that in LDL 2 (Pϭ0.000). The cholesterol-rich, buoyant LDL 1 particles contained Ϸ5 molecules of ␣-tocopherol per particle, whereas the cholesterolpoor, dense LDL 2 particles contained Ϸ1 molecule of ␣-tocopherol per particle (Table II) . The HAVA content in total LDL (LDL 1 plus LDL 2 ) was significantly higher in FDB subjects when compared with controls (0.063Ϯ0.020 versus 0.004Ϯ0.001 mol/mol apoB-100, PϽ0.001). LDL 1 HAVA content showed no differences between the 2 groups. LDL 2 particles in FDB contained significantly more HAVA molecules than did LDL 2 in controls. Furthermore, the HAVA content in LDL 2 was higher when compared with LDL 1 within and between the 2 groups (Table III) . The apoB-100 carbonyl group content in total LDL was somewhat but not significantly higher in FDB (0.21Ϯ0.08 versus 0.18Ϯ0.03 mol/mol apoB-100, Pϭ0.064). The LDL 1 apoB-100 carbonyl group content showed no differences between the 2 groups (0.05Ϯ0.02 versus 0.06Ϯ0.07 mol/mol apoB-100, Pϭ0.090), whereas LDL 2 particles in FDB contained significantly more carbonyl groups than did LDL 2 in controls (0.16Ϯ0.04 versus 0.12Ϯ0.03, PϽ0.01). The mean RT of LDL subfractions (reciprocal of fractional catabolic rate at steady state) derived by multicompartmental analysis is presented in Table III . The other kinetic parameters of apoB-containing lipoproteins in the subjects studied have been published previously and are not shown in detail. 8 The mean RT of total LDL (LDL 1 plus LDL 2 ) apoB-100 was Ͼ3-fold higher in FDB when compared with controls (147.2Ϯ19.3 versus 42.2Ϯ3.7 hours; PϽ0.001). In FDB, the mean RT of LDL 1 and LDL 2 particles was increased 2-fold and Ͼ4-fold, respectively, when compared with controls (Table III) . In both groups, significant, positive correlations were found between LDL 2 HAVA and LDL 2 RT ( Figure I ). In addition, in both groups, LDL 2 HAVA content was significantly correlated in a negative manner with LDL 2 ␣-tocopherol ( Figure II 
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LDL 1 HAVA, LDL 1 RT, LDL 1 ␣-tocopherol, and LDL 1 apoB-100 carbonyl group content, respectively.
Discussion
␥-Glutamyl semialdehyde is a primary oxidation product of both Pro and Arg side-chain residues. 5, 12, 13 By reduction with NaBH 4 , ␥-glutamyl semialdehyde forms HAVA. 6, 12, 13 Recently, HAVA has been shown to be a specific marker for apoB-100 oxidation in vitro and in normolipidemic subjects in vivo. 6 In that former study, the level of HAVA demonstrated in native total LDL obtained from 10 normolipidemic, young male volunteers was 0.012Ϯ0.004 mol/mol apoB-100 (0.4:10 000, Pro/Arg). The present work for the first time reports experiments with HAVA as a highly specific and sensitive marker of direct apoB-100 oxidation of circulating human LDL subfractions under pathophysiological conditions. Therefore, as a model, patients with heterozygous FDB showing a moderate to severe hypercholesterolemia were studied. The risk for the development of premature ischemic heart disease is strongly increased in FDB. 14 The apoB-100 defect (Arg3500Gln) primarily affects the fractional catabolism of LDL. 8, 15 The in vivo consequence of this has been shown to be a 2-fold higher RT of buoyant LDL 1 and a Ͼ4-fold higher RT of small LDL 2 in FDB when compared with controls. 8 The longer the RT of LDL, the longer is the exposure of its apoB-100 moiety to the attack of ROS. ApoB-100 consists of 4563 amino acids and has a molecular weight of 516 000 (minus the carbohydrate content). 16 ApoB-100 contains 170 Pro and 148 Arg residues that are partially susceptible to direct, oxidative damage in vivo. 6 HAVA is suggested to be formed by metal-catalyzed oxidation processes. 6 Apparently, Cu 2ϩ or Fe 2ϩ bind to discrete sites of apoB-100 and form centers for repeated radical production. The exact number of such binding sites is not known, and values ranging from 3 to Ϸ12 have been reported by others. 9, 17 However, participation of other ROS-generating processes, eg, myeloperoxidase reaction, in the formation of HAVA is unknown. The present study shows higher HAVA levels in total LDL in FDB subjects when compared with controls (1.97:10 000 versus 0.13:10 000 Pro/Arg, PϽ0.01). In controls, LDL 2 HAVA was higher when compared with LDL 1 , but in total it did not exceed the range demonstrated in healthy men elsewhere. 6 In FDB, apoB-100 of circulating LDL 2 contained significantly higher amounts of modified Pro/Arg residues when compared with controls. Here, the level of HAVA amounted to Ϸ12:10 000 Pro/Arg residues. There exists a strong association between the extremely higher RT of LDL 2 and the oxidative modification of apoB-100 Pro/Arg in FDB. These findings are consistent with the increment in nonspecific carbonyl group content in LDL 2 apoB-100 in FDB. In contrast, HAVA levels in LDL 1 particles were not increased in FDB, and no associations could be found with the RT of LDL 1 . In addition, qualitative changes in the LDL particles could render them more or less prone to oxidation. For instance, LDL ␣-tocopherol molecules are supposed to be good competitive substrates for oxidative attack. 7, 9 In hypercholesterolemic subjects, LDL ␣-tocopherol is suggested to be a predictor of LDL oxidizability. 9, 18 In the present study, LDL ␣-tocopherol levels were not different between the groups but were significantly higher in LDL 1 particles when compared with LDL 2 particles. LDL 2 ␣-tocopherol showed a strong, negative association with LDL 2 HAVA. Although there is no significant relationship between LDL 1 apoB-100 modification and LDL 1 ␣-tocopherol, the higher content of the antioxidant could provide an explanation for the lower extent of HAVA formation in LDL 1 . This is consistent with data published by others. 7, 9, 17, 18 In conclusion, because HAVA is not a normal constituent of human apolipoproteins, the overall yield of HAVA that has been found in LDL 2 apoB-100 is remarkably high in FDB and indicates that LDL apoB-100 Pro/Arg residues are good targets for oxidative attack under present pathophysiological conditions. Our data suggest that oxidative damage of a particularly small, more dense, ␣-tocopherol-poor, and "aged" LDL entity both in blood and in the subendothelium may be an important mechanism underlying the premature ischemic heart disease in FDB. However, additional work is needed to understand the specific consequences of ␥-glutamyl semialdehyde formation for the metabolic fate of apoB-containing lipoproteins in vivo.
